FIELD: medicine. SUBSTANCE: method involves administration of active phosphonate to person at amount at least about 0.1 LED and estrogenic hormone at amount about 0.2-0.8 LED per a day for the treatment course. Bisphosphonate or phosphonoalkylphosphonate is preferable active agent acting on bone. Method can be used for treatment human and animals with osteoporosis disease. EFFECT: decreased, delayed or prevented process of osseous tissue loss. 19 cl
Authors
Dates
1998-06-27—Published
1992-01-31—Filed